Samyang Biopharmaceuticals said that the Ministry of Food and Drug Safety has granted product approval for 2.5mg, 5mg, and 10mg of Everose, a breast cancer treatment.
|Samyang Biopharmaceuticals has received product approval for 2.5mg, 5mg, and 10mg of Everose, a breast cancer treatment, from the Food and Drug Safety Ministry. (Samyang Biopharmaceuticals)|
The drug, a generic version of Novartis' Afinitor, has additional indications for neuroendocrine, central nervous system, and kidney cancer. It is also the first everolimus product produced in Korea. Existing products have been dependent on imports.
Besides, Everose is the only product that has released the treatment in all three doses, 2.5, 5, and 10 mg, except for Afinitor, the company said.
“As the company has released the treatment in all three doses, we expect to provide a variety of prescription options to medical staff and increase the convenience of dispensing the drug,” a company official said. “Starting with breast cancer, we will try to improve the quality of life for patients with kidney and neuroendocrine cancer.”
<© Korea Biomedical Review, All rights reserved.>